Skip to main content
Premium Trial:

Request an Annual Quote

RXi, EyeGate to Collaborate on Ocular Delivery of RNAi Drugs


RXi Pharmaceuticals said this week that it has forged a collaboration with EyeGate Pharma to work on ocular delivery approaches for RNAi-based therapeutics.

The deal will evaluate EyeGate's iontophoresis technology in delivering RXi's self-delivering RNAi compounds in preclinical models, RXi said.

Each party will contribute technology, expertise, and resources to the effort, RXi said. Additional terms were not disclosed.